The current status of immunobased therapies for metastatic renal-cell carcinoma

The management of metastatic renal-cell carcinoma (mRCC) represents an important clinical challenge. Since being approved in the early 1990s, aspecific immunotherapy has been a mainstay of treatment for mRCC and the only therapy that has demonstrated long-term cures for mRCC. However, in recent time...

Descripción completa

Detalles Bibliográficos
Autores principales: Sathianathen, Niranjan J, Krishna, Suprita, Anderson, J Kyle, Weight, Christopher J, Gupta, Shilpa, Konety, Badrinath R, Griffith, Thomas S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723125/
https://www.ncbi.nlm.nih.gov/pubmed/29255699
http://dx.doi.org/10.2147/ITT.S134850
_version_ 1783285154473574400
author Sathianathen, Niranjan J
Krishna, Suprita
Anderson, J Kyle
Weight, Christopher J
Gupta, Shilpa
Konety, Badrinath R
Griffith, Thomas S
author_facet Sathianathen, Niranjan J
Krishna, Suprita
Anderson, J Kyle
Weight, Christopher J
Gupta, Shilpa
Konety, Badrinath R
Griffith, Thomas S
author_sort Sathianathen, Niranjan J
collection PubMed
description The management of metastatic renal-cell carcinoma (mRCC) represents an important clinical challenge. Since being approved in the early 1990s, aspecific immunotherapy has been a mainstay of treatment for mRCC and the only therapy that has demonstrated long-term cures for mRCC. However, in recent times there have been landmark advances made in the field of specific immunotherapy for a number of malignancies, including kidney cancer. This review outlines the range of immunobased agents currently available for the treatment of mRCC.
format Online
Article
Text
id pubmed-5723125
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-57231252017-12-18 The current status of immunobased therapies for metastatic renal-cell carcinoma Sathianathen, Niranjan J Krishna, Suprita Anderson, J Kyle Weight, Christopher J Gupta, Shilpa Konety, Badrinath R Griffith, Thomas S Immunotargets Ther Review The management of metastatic renal-cell carcinoma (mRCC) represents an important clinical challenge. Since being approved in the early 1990s, aspecific immunotherapy has been a mainstay of treatment for mRCC and the only therapy that has demonstrated long-term cures for mRCC. However, in recent times there have been landmark advances made in the field of specific immunotherapy for a number of malignancies, including kidney cancer. This review outlines the range of immunobased agents currently available for the treatment of mRCC. Dove Medical Press 2017-12-05 /pmc/articles/PMC5723125/ /pubmed/29255699 http://dx.doi.org/10.2147/ITT.S134850 Text en © 2017 Sathianathen et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Sathianathen, Niranjan J
Krishna, Suprita
Anderson, J Kyle
Weight, Christopher J
Gupta, Shilpa
Konety, Badrinath R
Griffith, Thomas S
The current status of immunobased therapies for metastatic renal-cell carcinoma
title The current status of immunobased therapies for metastatic renal-cell carcinoma
title_full The current status of immunobased therapies for metastatic renal-cell carcinoma
title_fullStr The current status of immunobased therapies for metastatic renal-cell carcinoma
title_full_unstemmed The current status of immunobased therapies for metastatic renal-cell carcinoma
title_short The current status of immunobased therapies for metastatic renal-cell carcinoma
title_sort current status of immunobased therapies for metastatic renal-cell carcinoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723125/
https://www.ncbi.nlm.nih.gov/pubmed/29255699
http://dx.doi.org/10.2147/ITT.S134850
work_keys_str_mv AT sathianathenniranjanj thecurrentstatusofimmunobasedtherapiesformetastaticrenalcellcarcinoma
AT krishnasuprita thecurrentstatusofimmunobasedtherapiesformetastaticrenalcellcarcinoma
AT andersonjkyle thecurrentstatusofimmunobasedtherapiesformetastaticrenalcellcarcinoma
AT weightchristopherj thecurrentstatusofimmunobasedtherapiesformetastaticrenalcellcarcinoma
AT guptashilpa thecurrentstatusofimmunobasedtherapiesformetastaticrenalcellcarcinoma
AT konetybadrinathr thecurrentstatusofimmunobasedtherapiesformetastaticrenalcellcarcinoma
AT griffiththomass thecurrentstatusofimmunobasedtherapiesformetastaticrenalcellcarcinoma
AT sathianathenniranjanj currentstatusofimmunobasedtherapiesformetastaticrenalcellcarcinoma
AT krishnasuprita currentstatusofimmunobasedtherapiesformetastaticrenalcellcarcinoma
AT andersonjkyle currentstatusofimmunobasedtherapiesformetastaticrenalcellcarcinoma
AT weightchristopherj currentstatusofimmunobasedtherapiesformetastaticrenalcellcarcinoma
AT guptashilpa currentstatusofimmunobasedtherapiesformetastaticrenalcellcarcinoma
AT konetybadrinathr currentstatusofimmunobasedtherapiesformetastaticrenalcellcarcinoma
AT griffiththomass currentstatusofimmunobasedtherapiesformetastaticrenalcellcarcinoma

Ejemplares similares